Silo Pharma (SILO) Fundamental Analysis: Revenue, Earnings & Valuation

1.83 / 10

Underperform

Fundamental rating is Underperform with a 1.8/10 score. Cost of sales ratio and liability proportion look acceptable, yet revenue growth is flat and other key metrics lag, indicating fragile financial health.

Analysis Checks(6/10)

Revenue-MV

Value-4.49

Score1/3

Weight28.56%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value0.00

Score1/3

Weight-2.25%

1M Return-0.38%

Inventory turnover ratio

Value47.95

Score2/3

Weight-6.56%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value51.48

Score2/3

Weight2.22%

1M Return0.36%

PB-ROE

Value-0.29

Score2/3

Weight53.64%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.12

Score3/3

Weight5.03%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-6.67%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value0.00

Score1/3

Weight-1.77%

1M Return-0.30%

Cost of sales ratio (%)

Value43.65

Score3/3

Weight1.67%

1M Return0.26%

Asset-MV

Value-0.49

Score0/3

Weight26.13%

1M Return4.00%

Is SILO undervalued or overvalued?

SILO scores 1.83/10 on fundamentals and holds a Premium valuation at present. Backed by its -74.56% ROE, -5863.50% net margin, -1.07 P/E ratio, 0.72 P/B ratio, and 57.98% earnings growth, these metrics solidify its Underperform investment rating.